[beta1 Integrin Dysfunction in Adult Chronic Myeloid Leukemia Bone Marrow Cells]

Area of Science:

• Hematology
• Cell Biology
• Oncology

Background:

• Previous studies indicated beta 1 integrin activation defects in K562 cells, a Ph(+) chronic myeloid leukemia (CML) cell line.
• Investigating these defects in primary bone marrow cells from CML patients is crucial for understanding disease mechanisms.

Purpose of the Study:

• To investigate beta 1 integrin activation and cell adhesion in bone marrow mononuclear cells (BMMNCs) from Ph(+) CML patients compared to normal individuals.
• To evaluate the effects of specific activators (8A2, GM-CSF, G-CSF) and an ABL tyrosine kinase inhibitor (CGP57148B) on CML BMMNCs.

Main Methods:

• Flow cytometry was used to assess 9EG7 epitope expression (indicating beta 1 integrin activation) and fibronectin (FN) binding.
• Bone marrow mononuclear cells (BMMNCs) from 12 Ph(+) CML patients and 10 normal donors were analyzed.
• Cells were treated with 8A2, GM-CSF, G-CSF, and CGP57148B to evaluate their effects.

Main Results:

• Ph(+) CML BMMNCs exhibited significantly lower beta 1 integrin activation and FN binding compared to normal BMMNCs after 8A2 activation.
• GM-CSF and G-CSF enhanced activation in normal BMMNCs but had no effect on CML BMMNCs.
• CGP57148B improved beta 1 integrin activation in CML BMMNCs but not in normal BMMNCs, suggesting a specific role for ABL kinase.

Conclusions:

• Defective beta 1 integrin activation is a primary cause of impaired cell adhesion in Ph(+) CML.
• The functional insufficiency of beta 1 integrin in CML BMMNCs is not directly reversible by the ABL tyrosine kinase inhibitor CGP57148B.